We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+29.99%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$815M
AUM Growth
+$109M
Cap. Flow
-$5.4M
Cap. Flow %
-0.66%
Top 10 Hldgs %
85.95%
Holding
32
New
5
Increased
2
Reduced
5
Closed
8

Top Buys

Rank Stock Value
1
ESPR
Esperion Therapeutics
ESPR
+$16.1M
2
LOXO
Loxo Oncology, Inc
LOXO
+$12.3M
3
ACOR
Acorda Therapeutics
ACOR
+$11.7M
4
MYOV
Myovant Sciences Ltd.
MYOV
+$9.73M
5
RXDX
Ignyta, Inc.
RXDX
+$7.49M

Top Sells

Rank Stock Value
1
AVXS
AveXis, Inc. Common Stock
AVXS
+$16.4M
2
ARDX icon
Ardelyx
ARDX
+$14.6M
3
AIMT
Aimmune Therapeutics
AIMT
+$13.9M
4
ABEO icon
Abeona Therapeutics
ABEO
+$5.54M
5
SBBP
Strongbridge Biopharma plc.
SBBP
+$5.47M

Sector Composition

Rank Sector Weight
1 Healthcare 97.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AKTX
26
Akari Therapeutics
AKTX
$14.4M
– –
-127
Closed -$714K
TENX icon
27
Tenax Therapeutics
TENX
$393M
– –
-75
Closed -$4.66M
ORKA
28
Oruka Therapeutics
ORKA
$5.31B
– –
-1,075
Closed -$662K
ACGN
29
DELISTED
Aceragen Inc
ACGN
– –
-16,561
Closed -$3.38M
SBBP
30
DELISTED
Strongbridge Biopharma plc.
SBBP
– –
-2,279,099
Closed -$5.47M
AIMT
31
DELISTED
Aimmune Therapeutics
AIMT
– –
-677,663
Closed -$13.9M
DMTX
32
DELISTED
Dimension Therapeutics, Inc
DMTX
– –
-928,199
Closed -$4.04M
1
2

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q1 2017 Portfolio in Review

As of Q1 2017, RA Capital Management held 32 positions worth $815M, up 16% from $706M the previous quarter. Its ten largest holdings account for 86% of the portfolio.

RA Capital Management's Q1 2017 filing shows 5 new, 2 increased, 5 reduced and 8 closed positions. Its largest new stake was Esperion Therapeutics: 704,701 shares worth $24.9M. The largest sale was AveXis, Inc. Common Stock, an estimated $16.4M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 97% a quarter earlier.

  • RA Capital Management's largest Q1 2017 buy was Esperion Therapeutics: 704,701 shares worth $24.9M.
  • RA Capital Management added most to Myovant Sciences Ltd. in Q1 2017, an estimated $9.73M increase.
  • RA Capital Management's biggest Q1 2017 reduction was AveXis, Inc. Common Stock, cutting an estimated $16.4M.
  • RA Capital Management fully exited Aimmune Therapeutics in Q1 2017, selling an estimated $13.9M.
  • RA Capital Management's ten largest holdings make up 86% of its $815M portfolio in Q1 2017.
  • RA Capital Management opened 5 new positions and closed 8 in Q1 2017.
  • RA Capital Management's portfolio value rose 16% quarter-over-quarter to $815M.

Based on RA Capital Management's 13F filing for Q1 2017, filed 15 May 2017.